JP2024527576A5 - - Google Patents

Info

Publication number
JP2024527576A5
JP2024527576A5 JP2024500409A JP2024500409A JP2024527576A5 JP 2024527576 A5 JP2024527576 A5 JP 2024527576A5 JP 2024500409 A JP2024500409 A JP 2024500409A JP 2024500409 A JP2024500409 A JP 2024500409A JP 2024527576 A5 JP2024527576 A5 JP 2024527576A5
Authority
JP
Japan
Prior art keywords
antigen
binding fragment
monoclonal antibody
antibody
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024500409A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024527576A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2022/000409 external-priority patent/WO2023281313A1/en
Publication of JP2024527576A publication Critical patent/JP2024527576A/ja
Publication of JP2024527576A5 publication Critical patent/JP2024527576A5/ja
Pending legal-status Critical Current

Links

JP2024500409A 2021-07-07 2022-07-06 抗tnfr2抗体及びその使用 Pending JP2024527576A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163219175P 2021-07-07 2021-07-07
US63/219,175 2021-07-07
PCT/IB2022/000409 WO2023281313A1 (en) 2021-07-07 2022-07-06 Anti-tnfr2 antibody and uses thereof

Publications (2)

Publication Number Publication Date
JP2024527576A JP2024527576A (ja) 2024-07-25
JP2024527576A5 true JP2024527576A5 (cg-RX-API-DMAC7.html) 2025-07-18

Family

ID=84800439

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024500409A Pending JP2024527576A (ja) 2021-07-07 2022-07-06 抗tnfr2抗体及びその使用

Country Status (9)

Country Link
EP (1) EP4367140A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024527576A (cg-RX-API-DMAC7.html)
KR (1) KR20240032985A (cg-RX-API-DMAC7.html)
CN (1) CN117980336A (cg-RX-API-DMAC7.html)
AR (1) AR126387A1 (cg-RX-API-DMAC7.html)
AU (1) AU2022308421A1 (cg-RX-API-DMAC7.html)
CA (1) CA3224693A1 (cg-RX-API-DMAC7.html)
TW (1) TW202309096A (cg-RX-API-DMAC7.html)
WO (1) WO2023281313A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL316894A (en) * 2022-05-26 2025-01-01 Pfizer ANTI-TNFR2 ANTIBODIES AND METHODS OF USE THEREOF
WO2024233258A1 (en) * 2023-05-05 2024-11-14 Cureimmune Therapeutics Inc. Anti-tnfr2 antibodies and uses thereof
WO2026119935A1 (en) 2024-12-03 2026-06-11 Resano Gmbh Combination comprising a tumor necrosis factor receptor 2 agonist
WO2026119926A1 (en) 2024-12-03 2026-06-11 Resano Gmbh Agonist polypeptide for use in treating and/or preventing heart failure

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017040312A1 (en) * 2015-08-28 2017-03-09 The General Hospital Corporation Agonistic anti-tumor necrosis factor receptor 2 antibodies
WO2019094559A2 (en) * 2017-11-09 2019-05-16 The General Hospital Corporation Antagonistic anti-tumor necrosis factor receptor superfamily polypeptides
US20210371537A1 (en) * 2018-09-18 2021-12-02 Merrimack Pharmaceuticals, Inc. Anti-tnfr2 antibodies and uses thereof
CN113874083A (zh) * 2019-03-01 2021-12-31 梅里麦克制药股份有限公司 抗-tnfr2抗体及其用途
EP3907240A4 (en) * 2019-08-02 2023-02-22 Jiangsu Simcere Pharmaceutical Co., Ltd. ANTI-TNFR2 ANTIBODIES AND USE THEREOF
AU2020348224A1 (en) * 2019-09-17 2022-05-12 Apexigen, Inc. Anti-TNFR2 antibodies and methods of use
CN112480259B (zh) * 2021-02-05 2021-05-04 百奥赛图(北京)医药科技股份有限公司 抗tnfr2抗体及其用途

Similar Documents

Publication Publication Date Title
Wang et al. Development of therapeutic antibodies for the treatment of diseases
JP7685095B2 (ja) 多重特異性抗体とその作製及び使用方法
KR102068600B1 (ko) Pdl-1 항체, 그 약학적 조성물 및 그 용도
JP7844558B2 (ja) リンパ球における阻害経路の中和
TWI771361B (zh) 人程序性死亡受體pd-1的單株抗體及其片段
JP2022526764A5 (cg-RX-API-DMAC7.html)
JP2021531764A5 (cg-RX-API-DMAC7.html)
JP2021533726A5 (cg-RX-API-DMAC7.html)
JP2021515565A5 (cg-RX-API-DMAC7.html)
JP2021516973A5 (cg-RX-API-DMAC7.html)
JP2021516974A5 (cg-RX-API-DMAC7.html)
JP2022533538A5 (cg-RX-API-DMAC7.html)
JP2020520370A5 (cg-RX-API-DMAC7.html)
JP2010504755A5 (cg-RX-API-DMAC7.html)
CN116948035A (zh) 多特异性抗体及其制备和使用方法
JP2024518947A (ja) Dll3及びpd-1を標的とする組み合わせ療法のための投与レジメン
JP2023517794A5 (cg-RX-API-DMAC7.html)
WO2023040940A1 (zh) Pvrig/tigit结合蛋白联合免疫检查点抑制剂用于治疗癌症
JP2024528682A (ja) 薬物組成物及び用途
CN112351794A (zh) 用于尿路上皮癌的免疫治疗方法
WO2021115303A1 (zh) 一种抗Claudin18.2单克隆抗体、其制备方法及用途
JP2025511288A (ja) 抗pvrig抗体、その医薬組成物及びその使用
CN111094339A (zh) 抗pd-1抗体和抗lag-3抗体联合在制备治疗肿瘤的药物中的用途
JP2022517216A (ja) 組換え抗ヒトpd-1抗体およびその用途
JP2022502079A5 (cg-RX-API-DMAC7.html)